

DAFTAR PUSTAKA

- Aben, L., Heijenbrok K. M. H., van Loon, E. M., 2013. Training memory self efficacy in the chronic stage after stroke: a randomized controlled trial. *Neurorehabil Neural Repair*, Vol. 27, p. 110-117. doi: 10.1177/1545968312455222.
- Abraham, C. S., Harada, N., Deli, M. A., dan Niwa, M., 2002. Transient forebrain ischemia increases the blood-brain barrier permeability for albumin in stroke-prone spontaneously hypertensive rats. *Cell Mol Neurobiol*, Vol. 22 No. 4, p. 455–62. doi: 10.1023/A:1021067822435.
- AHA, 2018. Heart disease and stroke statistics 2018 update: a report from the american heart association. *American Heart Association*. doi: 10.1161/CIR.0000000000000558.
- Aluclu, M. U., Acar, A., Guzel, A., Bahceci, S., dan Yaldiz, M., 2007. Evaluation of erythropoietin effects on cerebral ischemia in rats. *Neuroendocrinology Letters*, Vol. 28 No. 2, p. 170–174.
- Araujo, A. S., Lobo, C. L. C., Covas, D. T., Costa, F. F., Medeiros, L., Cancado, R. D., Gualandro, S. F. M., dan Saad, S. T. O., 2014. Guidelines on the treatment of anemia of chronic renal failure using recombinant human erythropoietin. *Rev Bras Hematol Hemoter*, Vol. 36 No. 6, p. 450-453. doi: 10.1016/j.bjhh.2014.09.009.
- Azmandian, J., Abbasi, M. R., Pourfarziani, V., Nasiri, A. A., Ossareh, S., Jahromi, S. E., Sanadgol, H., Amini, S., dan Farahani, A. S., 2018. Comparing therapeutic efficacy and safety of epoetin beta and epoetin alfa in the treatment of anemia in end-stage renal disease hemodialysis patients. *American Journal of Nephrology*, Vol. 48, p. 251-259. doi: 10.1159/000493097.
- Banks, W. A., Jumbe, N. L., Farrell, C. L., Niehoff, M.L., dan Heatherington, A. C., 2004. Passage of erythropoietic agents across the blood-brain barrier: a comparison of human and murine erythropoietin and the analog darbepoetin alfa. *Eur J Pharmacol*, Vol. 505 No. 13, p. 93–101. doi: 10.1016/j.ejphar.2004.10.035.

- Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., Lenerolle, N. C., Cerami, C., Itri, L. M., dan Cerami, A., 2000. Erythropoietin crosses the blood brain barrier to protect against experimental brain injury. *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 97 No. 19, p. 10526-10531. doi: 10.1073/pnas.97.19.10526.
- Caplan, L. R., 2011. Stroke Classification - A Personal View. *American Heart Association Journal*, Vol. 42, p. S3-S6. doi: 10.1161/STROKEAHA.110.594630.
- Catania, M. A., Marciano, M. C., Parisi, A., Sturiale, A., Buemi, M., Grasso, G., Squadrito, F., Caputi, A. P., dan Calapai, G., 2002. Erythropoietin prevents cognition impairment induced by transient brain ischemia in gerbils. *European Journal of Pharmacology*, Vol. 437 No. 3, p. 147–150. doi: 10.1016/s0014-2999(02)01292-x.
- Dahlberg, S. A., Xu, L., Hess, D.C., Hohnadel, E., Hill, W. D., dan Fagan, S.C., 2004. Erythropoietin and erythropoietin mimetic peptide in focal cerebral ischemia. *Stroke*. Vol. 35, p. 279.
- Davalos, A., Sabin, J. A., Castillo, J., Tejedor, E. D., Ferro, J., Vila, E. M., Serena, J., Segura, T., Cruz, V. T., Masjuan, J., Cabo, E., dan Secades, J. J., 2012. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study. *The Lancet*, Vol. 380 No. 9839, p. 349-357. doi: 10.1016/s0140-6736(12)60813-7.
- Deb, P., Sharma, S. dan Hassan, K. M., 2010. Pathophysiologic mechanisms of acute ischemic stroke: An overview with emphasis on therapeutic significance beyond thrombolysis. *Pathophysiology*, Elsevier Ireland Ltd, Vol. 17 No. 3, p. 197–218. doi: 10.1016/j.pathophys.2009.12.001.
- Digicaylioglu, M., Bichet, S., Marti, H. H., Wenger, R. H., Rivas, L. a, Bauer, C., dan Gassmann, M., 1995. Localization of specific erythropoietin binding sites in defined areas of the mouse brain. *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 92 No. 9, p. 3717–3720. doi: 10.1073/pnas.92.9.3717
- Ehrenreich, H., Degner, D., dan Meller, J., 2004. Erythropoietin: a candidate

compound for neuroprotection in schizophrenia. *Mol Psychiatry*, Vol. 9, p. 42-54.

Elliot, S., Pham, E., dan Macdougall, C., 2008. Erythropoietins: A common mechanism of action. *Experimental Hematology*, Vol. 36, p. 1573-1584. doi: 10.1016/j.exphem.2008.08.003.

Erbayraktar, S., Yilmaz, O., Gokmen, N., dan Brines, M., 2003. Erythropoietin is a multifunctional tissue-protective cytokine. *Curr Hematol Rep*, Vol. 2, p. 465-470.

Faure, S., Oudart, N., Javellaud, James F., Albert W., David G., dan Achard, J. M., 2006. Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil. *Journal of Hypertension*, Vol. 24 No. 11, p. 2255–2261. doi: 10.1097/01.hjh.0000249704.34607.4c.

Fernandez, H., Rey, R., Lopez, A., Mato, M. P., Sobrino, T., Castillo, J., dan Campos, F., 2017. Inclusion criteria update for the rat intraluminal ischaemic model for preclinical studies. *Disease Models and Mechanisms*, Vol. 10, p. 1433-1438. doi: 10.1242/dmm.029868.

Flicker, L. dan Evans, J. G., 2012. Piracetam for dementia or cognitive impairment. *Cochrane Database of Systematic Reviews*. doi: 10.1002/14651858.CD001011.

Ginsberg, M. D., 2008. Neuroprotection for ischemic stroke: past, present, and future. *Neuropharmacology*, Vol. 55 No. 3, p. 363-369. doi: 10.1016/j.neuropharm.2007.12.007.

Gonzalez, F. F., Abel R., Almli, C. R., Mu, D., Wendland, M., dan Ferriero, D. M., 2009. Erythropoietin sustains cognitive function and brain volume after neonatal stroke. *Developmental Neuroscience*, Vol. 31 No. 5, p. 403–411. doi: 10.1159/000232558.

Hoeber, D., Sifringer, M., Looij, Y. V., Herz, J., Sizonenko, S. V., Kempe, K., Serdar, M., Palasz, J., Hadamitzky, M., Endesfelder, S., Fenderey, J., Muser, U. F., dan Bendix, I., 2016. Erythropoietin Restores Long-Term Neurocognitive Function Involving Mechanisms of Neuronal Plasticity in a Model of Hyperoxia-Induced Preterm Brain Injury. *Oxidative Medicine and Cellular*

Longevity, Vol. 2016. doi: 10.1155/2016/9247493.

- Hoke, A., 2006. Neuroprotection in the peripheral nervous system. *Archives of Neurology*, Vol. 63 No.12, p. 1681-1683. doi: 10.1001/archneur.63.12.1681.
- Hralova, M., Plananska, E., Angerova, Y., Jadwischczokova, A., Bortelova, J., Grunerova, M. L., dan Maresova, D., 2014. Effects of a single dose of erythropoietin on motor function and cognition after focal brain ischemia in adult rats. *Prague Medical Report*, Vol. 115 No. 1–2, p. 5–15. doi: 10.14712/23362936.2014.1.
- Jerndal, M., Forsberg, K., Sena, E. S., Macleod, M. R., O'Collins, V. E., Linden, T., Nilsson, M., dan Howells, D. W., 2010. A systematic review and meta-analysis of erythropoietin in experimental stroke. *Journal of Cerebral Blood Flow and Metabolism*, Vol. 30 No. 5, p. 961–968. doi: 10.1038/jcbfm.2009.267.
- Kolb, B., Morshead, C., Gonzales, C., Kim, M., Gregg, C., Shingo, T., dan Welss, S., 2007. Growth factor-stimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats. *Journal of Cerebral Blood Flow and Metabolism*, Vol. 27, p. 983–997. doi: 10.1038/sj.jcbfm.9600402.
- Korsmeyer, S. J., Wei, M. C., Saito, M., Weiler, S., Oh, K. J., dan Schlesinger, P. H., 2000. Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c. *Cell Death and Differentiation*, Vol. 7, p. 1166–1173. doi: 10.1038/sj.cdd.4400783.
- Kuraoka, M., Furuta, T., Matsuwaki, T., Omatsu, T., Ishii, Y., Kyuwa, S., dan Yoshikawa, Y., 2009. Direct experimental occlusion of the distal middle cerebral artery induces high reproducibility of brain ischemia in mice. *Exp Anim*, Vol. 58 No. 1, p. 19-29.
- Li, Y., Lu, Z., Keogh, C. L., Yu, S. P., dan Wei, L., 2006. Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice. *J. Cereb. Blood Flow Metab.* Vol. 27, p. 1043–1054. doi: 10.1038/sj.jcbfm.9600417.
- Li, Y., Lu, Z. Y., Ogle, M., dan Wei, L., 2007. Erythropoietin prevents blood

brain barrier damage induced by focal cerebral ischemia in mice. *Neurochem Res.* Vol. 32, p. 2132–2141. doi: 10.1007/s11064-007-9387-9.

Li, L., Jiang, Q., Ding, G., Zhang, L., Zhang, Z. G., Li, Q., Panda, S., Kapke, A., Lu, M., Ewing, J. R., dan Chopp, M., 2009. MRI identification of white matter reorganization enhanced by erythropoietin treatment in a rat model of focal ischemia. *Stroke.* Vol. 40, p. 936–941. doi: 10.1161/strokeaha.108.527713.

Lourhmati, A., Buniatian, G. H., Paul, C., Verleysdonk, S., Buecheler, R., Buadze, M., 2013. Age dependent astroglial vulnerability to hypoxia and glutamate: The role for erythropoietin. *PloS One*, Vol. 8, No. e77182. doi: 10.1371/journal.pone.0077182.

Luca, R. D., Leonardi, S., Spadaro, L., Russo, M., Aragona, B., Torrisi, M., Maggio, M. G., Bramanti, A., Naro, A., Cola, M. C. D., dan Calabro, R. C., 2017. Improving cognitive function in patients with stroke: can computerized training be the future. *Journal of Stroke and Cerebrovascular Diseases.* doi: 10.1016/j.jstrokecerebrovasdis.2017.11.008.

Macdougall, I. C., Robson, R., Opatrna, S., Liogier, X., Pannier, A., Jordan, P., Dougherty, F. C., dan Reigner, B., 2006. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. *Clin J Am Soc Nephrol*, Vol. 1, p. 1211–1215. doi: 10.2215/40CJN.00730306.

Mancini, D. M., Katz, S. D., Lang, C. C., LaManca, J., Hudaihed, A., Androne, A. S., 2003. Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. *Circulation*, Vol. 107, p. 294-299. doi: 10.1161/01.CIR.0000044914.42696.6A.

Marsili, A., Puorro, G., Pane, C., Rosa, A., Defazio, G., Casali, C., Cittadini, A., Michele, G., Florio, B. E., Filla, A., dan Sacca, F., 2017. Stability of erythropoietin repackaging in polypropylene syringes for clinical use. *Study Pharmaceutical Journal*, Vol. 25, p. 290-293. doi: 10.1016/j.jsps.2016.01.003.

- Marti, H. H., Gassmann, M., Wenger, R. H., 1997. Detection of erythropoietin in human liquor: intrinsic erythropoietin production in the brain. *Kidney Int*, Vol. 51, p. 416–418. doi: 10.1038/ki.1997.55.
- Mentari, I. A., Naufalina, R., Rahmmadi, M., dan Khotib, J., 2018. Development of ischemic stroke model by right unilateral common carotid artery occlusion (rUCCAO) method. *Fol Med Indones*, Vol. 54 No. 3 September 2018, p. 200-206. doi: 10.20473/fmi.v54i3.10015.
- Mir, M. A., Al-Baradie, R. S., dan Alhussainawi, M. D., 2014. Pathophysiology of Strokes. *Recent Advances in Stroke Therapeutics*, NOVA Science Publishers USA, in book : Recent Advances In Stroke Therapeutics.
- Moon, C., Krawczyk, M., Ahn, D., 2003. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. *Pros Natl Acad Sci USA*, Vol. 100, p. 11612-11617. doi: 10.1073@pnas.1930406100.
- Nair, R. D., Lincoln, N. B., 2007. Cognitive rehabilitation for memory deficits following stroke, *Cochrane Database Syst Rev*, Vol. 3 No. CD002293.
- Netea, M. G., Joosten, L. A. B., Lewis, E., 2006. Deficiency of interleukin-18 in mice leads to hyperphagia, obesity, and insulin resistance. *Nature Medicine*, Vol. 12 No. 6, p. 650-656. doi: 10.1038@nm1415.
- Ng, T., Marx, G., dan Macdugall, I., 2003. Recombinant erythropoietin in clinical practice. *Postgrad Med J*, Vol. 79, p. 367-376. doi: 10.1136/pmj.79.933.367
- NKF KDOQI guidelines [Internet]. 2006 [cited 2019 January 20]. Available from:
http://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_anemiaUP/guide1.htm.
- Noguchi, C. T., Asavaritikrai, P., teng, R., dan Jia, Y., 2007. Role of erythropoietin in the brain. *Crit Rev Oncol Hematol*, Vol. 64 No. 2,

p. 159-171. doi: 10.1016/j.critrevonc.2007.03.001.

- Oomen, C. A. Farkas, E., Roman, V., Beek, E. M., Luiten, P. G. M., dan Meerlo, P., 2009. Resveratrol preserves cerebrovascular density and cognitive function in aging mice materials and methods. *Frontiers in Aging Neuroscience*, Vol. 1 No. 4, p. 1–9. doi: 10.3389/neuro.24.004.2009.
- Ponce, L. L., Navarro, J. C., Ahmed, O., Robertson, C. S., 2013. Erythropoietin neuroprotection with traumatic brain injury. *Pathophysiology*, Elsevier Ireland Ltd, Vol. 20 No. 1, p. 31–38. doi: 10.1016/j.pathophys.2012.02.005.
- Pugh, C. W., dan Ratcliffe, P. J., 2003. Regulation of angiogenesis by hypoxia: role of the HIF system. *Nature Medicine*, Vol. 9 No. 6, p. 677–684. doi: 10.1038/nm0603-677.
- Puri, S. K., 2003. Cerebral edema and its management. *Medical Journal Armed Forces India*, Vol. 59 No. 4, p. 326–331. doi: 10.1016/S0377-1237(03)80147-8
- Rostamian, S., Mahinrad, S., Stijnen, T., Sabayan, B., dan Craen, A. J. M., 2014. Cognitive Impairment and Risk of Stroke A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *Stroke*, Vol. 45 No. 5, p. 1342–1348. doi: 10.1161/strokeaha.114.004658.
- Semenza, G. L., dan Wang, G. L., 1992. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Molecular and Cellular Biology*, Vol. 12 No. 12, p. 5447–5454. doi:10.1128/mcb.12.12.5447.
- Shilpa, D., Kadama, B., Justin, D., Mulhollanda, Dani, R., Smithd, Michael, V., Johnstona, B., C., dan Anne, M. C., 2009. Chronic brain injury and behavioral impairments in a mouse model of term neonatal strokes. *Behav Brain Res*, Vol. 197 No. 1, p. 77–83. doi: 10.1016/j.bbr.2008.08.003.
- Silva, B., Sousa, L., Miranda, A., Vasconcelos, A., Reis, H., Barrcelos, L., Arantes, R., Teixeira, A., dan Rochid, M. A., 2015. Memory deficit associated with increased brain proinflammatory cytokine levels and

- neurodegeneration in acute ischemic stroke. *Arquivos de Neuro-Psiquiatria*, Vol. 73 No. 8, p. 655–659. doi: 10.1590/0004-282X20150083.
- Sims, B., Clarke, M., Njah, W., Hopkins, E. S., dan Sontheimer, H., 2010. Erythropoietin induced neuroprotection requires cysteine glutamate exchanger activity. *Brain Research*, Vol. 1321, p. 88-95. doi: 10.1016/j.brainres.2010.01.040.
- Siren, A. L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gletler, C., Pasquali, C., Capobianco, A., Mennini, T., Heumann, R., Cerami, A., Enhrenreich, H., dan Ghezzi, P., 2001. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. *Journal of Head Trauma Rehabilitation*, Vol. 98 No. 7, p. 4044–4049. doi: 10.1097/00001199-199606000-00012.
- Snapchaan, L., de Leeuw, F. E., 2007. Poststroke memory function in nondemented patients: a systematic review on frequency and neuroimaging correlates. *Stroke*, Vol. 38, p. 198-203. doi: 10.1161/01.STR.0000251842.34322.8f.
- Sooling, C., 2011. Organ-protective and immunomodulatory effects of erythropoietin – an update on recent clinical trials. *Basic and Clinical Pharmacology and Toxicology*, Vol. 110, p. 113-121. doi: 10.1111/j.1742-7843.2011.00820.x.
- Stephenson, D. G., 1996. The Hippocampus, Long-Term Potentiation And Memory. *Clinical and Experimental Pharmacology and Physiology*, Vol. 23, p. 961-964. doi: 10.1111/j.1440-1681.1996.tb01149.x.
- Strong, K., Mathers, C., dan Bonita, R., 2006. Acute stroke, *Priority Disease and Reasons for Inclusion*, Vol. 6, p. 68–71.
- Villa, P., van Beek, J., Larsen, A. K., Gerwien, J., Christensen, S., Cerami, A., Brines, M., Leist, M., Ghezzi, P., dan Torup, L., 2007. Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. *J Cereb Blood Flow Metab*. Vol. 27, p. 552–563. doi: 10.1038/sj.jcbfm.9600370.

- Volpe, B. T., Waczek, B., dan Davis, H. P., 1988. Modified T-maze training demonstrates dissociated memory loss in rats with ischemic hippocampal injury. *Behavioural Brain Research*, Vol. 27 No. 3, p. 259–268. doi: 10.1016/0166-4328(88)90122-2.
- Wahl, D., Coogan, S. C. P., Biet, S. M. S., Cabo, R., Haran, J. B., Reubenheimer, D., Cogger, V. C., Mattson, M. P., Simpson, S. J., dan Couteur, D. G. L., 2017. Cognitive and behavioral evaluation of nutritional interventions in rodent models of brain aging and dementia. *Clinical Interventions in Aging*, Vol. 12, p. 1419–1428. doi: 10.2147/CIA.S145247.
- Wang, G. L., Jiang, B. H., Rue, E. A., dan Semenza, G. L., 1995. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proceedings of the National Academy of Sciences of the United States of America*, Vol. 92 No. 12, pp. 5510-5514. doi: 10.2307/2367546.
- Wang, L., Zhang, Z., Wang, Y., Zhang, R., dan CHopp, M., 2004. Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. *Stroke*, Vol. 35, p. 1732-1737. doi: 10.1161/01.STR.0000132196.49028.a4.
- Wang, Y., Zhang, Z. G., Rhodes, K., Renzi, M., Zhang, R. L., Kapke, A., Lu, M., Pool, C., Heavner, G., dan Chopp, M., 2007. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. *Br J Pharmacol*. Vol. 151, p. 1377–1384. doi: 10.1038/sj.bjp.0707285.
- Weiss, M. J., 2003. New insights into erythropoietin and epoetin alfa: mechanisms of action, target tissues, and clinical applications. *The Oncologist*, Vol. 8, p. 18-29. doi: 10.1634/theoncologist.8-suppl_3-18.
- Wen, T. C., Sadamoto, Y., Tanaka, J., Zhu, P. X., Nakata, K., Ma, Y. J., 2002. Erythropoietin protects neurons against chemical hypoxia and cerebral ischemic injury by up regulating Bcl-xl expression. *Journal of Neuroscience Research*, Vol. 67, p. 795-803. doi: 10.1002/jnr.10166.

- Xiong, Y., Chopp, M., Lee, C. P., 2009. Erythropoietin improves brain mitochondrial function in rats after traumatic brain injury. *Neurol res*, Vol. 31, p. 496-502.
- Yamamoto, Y., Shioda, N., Han, F., Moriguchi, S., Nakajima, A., Yokosuka, A., Mimaki, Y., Sashida, Y., Yamakuni, T., Ohizumi, Y., dan Fukunaga, K., 2009. Nobiletin improves brain ischemia-induced learning and memory deficits through stimulation of CaMKII and CREB phosphorylation. *Brain Research*. Elsevier B.V., Vol. 1295, p. 218–229. doi: 10.1016/j.brainres.2009.07.081.
- Yan, F., Zhang, M., Meng, Y., Li, H., Yu, L., Fu, X., Tang, Y., dan Jiang, C., 2016. Erythropoietin improves hypoxic-ischemic encephalopathy in neonatal rats after short-term anoxia by enhancing angiogenesis. *Brain Res*. Vol. 1651, p. 104–113. doi: 10.1016/j.brainres.2016.09.024.
- Yoo, S. J., Cho, B., Lee, D., Son, G., Lee, Y. B., Han, H. S., Kim, E., Moon, C., Moon, C., 2017. The erythropoietin derived peptide MK-X and erythropoietin have neuroprotective effects against ischemic brain damage. *Cell Death and Disease*. Vol. 8, p. 1-13. doi: 10.1038/cddis.2017.381.